Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.4 (
adenosine deaminase
)
5,136
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A fourteen-year old female presented with a mediastinal mass and pleural effusion. A diagnosis of a poorly differentiated lymphocytic lymphoma was made from a lymph node biopsy. Fluid from a pleural
tap
contained numerous lymphoblasts; 91.5% of these lymphoblasts had a thymus leukemic antigen. At presentation, although morphologically normal, no
adenosine deaminase
(
ADA
) activity could be demonstrated in her peripheral blood lymphocytes. Lysates of her lymphocytes mixed with lysates of lymphocytes with known
ADA
activity resulted in
ADA
activity that was greater than expected. With disappearance of tumor following the institution of therapy,
ADA
activity appeared in her lymphocytes and the above phenomenon disappeared.
...
PMID:Transient stimulatory adenosine deaminase activity in peripheral lymphocyte lysates from a case of T-cell lymphoma. 689 85
The aim of this experimental study was to investigate the possible role of nitric oxide (NO) and the activities of
adenosine deaminase
(
ADA
) and xanthine oxidase (XO) in the pathogenesis of isoniazid (INH)-induced oxidative damage in red blood cells (RBCs), and also to show the effect of caffeic acid phenethyl ester (CAPE) and erdosteine, antioxidants, in decreasing this toxicity. A total of 25 adult male rats were divided into four experimental groups as follows: control group (n = 7), INH-treated group (n = 6), INH + CAPE-treated group (n = 6), and INH + erdosteine-treated group (n = 6). INH, INH-CAPE, and INH-erdosteine-treated groups were treated orally with INH 50 mg/kg daily and with the
tap
water for 15 days. Control group was given only
tap
water. CAPE was intraperitoneally injected for 15 days at a dose of 10 micromol/kg. Erdosteine was treated orally for 15 days at a dose of 10 mg/kg/day. The injection of INH led to a significant increase in the activities of
ADA
, XO, and NO levels in RBCs of rats. Co-treatment with CAPE caused a significant decrease in the activities of
ADA
and XO and the levels of NO in RBCs. In addition, co-treatment with erdosteine caused a significant decrease in the activities of
ADA
and XO and the levels of NO in RBCs. The results of this study showed that
ADA
, XO, and NO may play an important role in the pathogenesis of INH-induced oxidative stress in RBCs. CAPE and erdosteine may have protective potential in this process and they may become a promising drug in the prevention of this undesired side effect of INH.
...
PMID:Protective role of caffeic acid phenethyl ester and erdosteine on activities of purine-catabolizing enzymes and level of nitric oxide in red blood cells of isoniazid-administered rats. 1903 79
